The IBD Training Academy is a year-long educational programme, starting in March 2022, for certified gastroenterologists from across Europe with an active interest in IBD.
The programme is funded by Galapagos, with content developed by OPEN Health following guidance and endorsement from a steering committee of leading independent expert gastroenterologists. This programme will contain mention of Jyseleca®▼ (filgotinib) as part of a fair and balanced discussion about treatment options for IBD.
Prescribing Information and Adverse Event reporting for Great Britain:
Prescribing Information and Adverse Event reporting for Ireland:
Jyseleca 100 mg and 200 mg available here
For the rest of Europe, please refer to the Belgium PI here
This page is the hub for the IBD Training Academy and will host all the programme content, as well as further information about your mentors.
Don’t miss the short video below that summarises the key milestones of the Training Academy programme and celebrates your achievements! Hear our expert steering committee share what they thought of the programme and the value it has to offer.
In recognition of the time you have spent on the programme, the IBD Training Academy has been awarded Continued Professional Development (CPD) accreditation for each completed module.
To ensure that you do not miss the opportunity to achieve CPD learning points, access to the online learning portal and resources will be extended until September 2023 for completion.
After you have completed a module, including any on-demand resources, please email us at IBDTrainingAcademy@openhealthgroup.com with evidence of completion, such as your eLearning quiz score. We will then send you an official CPD certificate of completion, signed by the steering committee, containing the number of hours spent on each module, which corresponds to the number of allocated points.
When you have received your CPD certificate of completion, it can be used as part of your own personal development record.
For more information on how to claim CPD credits, please visit the official help page here.
To celebrate the beginning of the IBD Training Academy we held a live, on-line launch meeting on Wednesday 30th March, with the module mentors and participants. If you missed this meeting, please watch the video below.
If you have any questions please do reach out to us using the contact details below.
This meeting took place on Wednesday 15 March, 18:00–19:30 CET. If you were unable to attend the live session, please watch the recording below.
We were joined by the IBD Training Academy faculty and your fellow peers to celebrate the end of the programme. This was an opportunity to share your key learnings, consult with the experts in small groups, and consider the changes you are going to make to your own clinical practice going forward.
The programme, presented and hosted by the steering committee and guest faculty, comprises a total of six modules, each made up of a mix of educational, mentoring and networking activities, including two world-renowned Centres of Excellence.
The modules are designed to be practical and interactive, so please do bring your questions to the live webinars and mentoring sessions to make the most of the opportunities with the experts.
Each module will be spread across 2 months, excluding Module 1, which is shorter.
Content will be released throughout the year as it becomes available.
The expert steering committee will lead, present and act as mentors for the duration of the programme. Each module is led by two steering committee members who have aligned their particular expertise to the topics that will be covered.
Raja Atreya is Professor for Translational Immunology in IBD, senior physician and head of the IBD Unit, Outpatient Clinic and Clinical Study Centre at University Hospital Erlangen, Germany. His work focusses on identifying response predictors (e.g. molecular endoscopy) and mechanisms of resistance to biological therapies in IBD. His career has been well decorated – he received the Theodor-Frerichs Award of the German Society for Internal Medicine, the Paul Ehrlich and Ludwig Darmstaedter Prize for Young Researchers from the Paul Ehrlich Foundation, and the United European Gastroenterology’s Rising Star Award.
Flavio Caprioli is Associate Professor of Gastroenterology at the University of Milan, Italy. His areas of expertise are preclinical research, mucosal and systemic immunology, and translational research in IBD. His PhD focussed on mechanisms of autocrine regulation of IL-21 in humans and the role of IL-21 in inducing naïve T-cell polarisation towards effector Th17 lymphocytes. He has since studied the role of IL-21 as a promoter of systemic and intestinal inflammation and the neutralisation of this cytokine as a potential new therapeutic approach in autoimmune-related inflammatory diseases.
Mathurin Fumery is a consultant gastroenterologist at the University of Picardy Jules Verne and Professor of Gastroenterology at Amiens University Hospital, France. His research focusses on the epidemiology of IBD, and he is involved in the French IBD epidemiology registry, EPIMAD. Professor Fumery has published extensively in the area of IBD, particularly around biologic treatments and population-based IBD epidemiology.
Ana Gutiérrez is Head of the Gastroenterology Section at Hospital General Alicante, Spain. She is Vice President of the governing board of the Spanish IBD group, GETECCU, where she also acts as the director of training courses in IBD, and is the national representative of Spain within the European Crohn’s and Colitis Organisation. Her PhD and postdoctoral research at the University of Miguel Hernández, Spain, focussed on the value of fibrinolytic tests in patients with acute upper gastrointestinal haemorrhage.
Professor Taku Kobayashi
Centre for Advanced IBD Research and Treatment, Kitasato University Kitasato
Institute Hospital, Tokyo, Japan
Taku Kobayashi is Vice Director and Associate Professor at the Centre for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan. He is Director of the International Exchange Committee of the Japanese Society of IBD and a Clinical Research Committee member for the Asian Organization for Crohn’s and Colitis. He serves as a councillor for several Japanese gastroenterology societies. His current projects include global, prospective, randomised controlled trials and the development of prospective registries of Japanese patients with IBD.
Dr Gareth Parkes
Royal London Hospital, UK
Gareth Parkes is Clinical Lead for Gastroenterology at the Royal London Hospital, UK. His interests include IBD clinical trials, the role of the microbiota and probiotics, and the use of technology in the IBD clinic. He has sat on the British Society of Gastroenterology IBD Committee and has a range of publications in the fields of IBD, gastrointestinal microbiota and irritable bowel syndrome. He is Co-Founder and Medical Director of Ampersand Health, which developed the award-winning app ‘My IBD Care’, using digital technology and behavioural science to improve patients’ lives.
Stefan Schreiber gained his medical degree at the University of Hamburg. After two fellowships he joined the Department of Gastroenterology at Charité University Hospital, Berlin. In 1996 he became Associate Professor at Christian-Albrecht University. He became full Professor of Medicine in 1999; in 2004 he became Director of the Department of Internal Medicine I and head of the Institute of Clinical Molecular Biology at Kiel University. His research interests span the genetics and pathophysiology of intestinal inflammation, IBD therapy development and human ageing. He has authored more than 1000 original publications.
Séverine Vermeire trained at KU Leuven, the National University of Asunción, Paraguay, the Wellcome Trust Centre for Human Genetics, Oxford, UK, and Montreal General Hospital, Canada. Since 2003, she has been a member of the Gastroenterology Department at University Hospitals Leuven and professor of medicine at KU Leuven. She became head of the Department of Chronic Diseases and Metabolism at KU Leuven in 2016. Her work has led to more than 500 peer-reviewed articles and focusses on the role of the microbiome, genetic susceptibility in IBD and signatures predictive of therapy response.